Humanigen logo
Humanigen HGEN
report update icon

Quarterly report 2023-Q1
added 05-23-2026

Humanigen Balance Sheet 2022-2009 | HGEN

Brief overview of Humanigen's assets and capital

Balance sheet changes are traced across five available annual reports between 2014 and 2021.

The asset base progressed from $43 million to $71.1 million, equal to +65.3% overall and about 7.4% per year.

Liability growth of +415.9% exceeded asset growth of +65.3%, increasing reliance on outside funding.

The period ended with negative equity, a structure associated with elevated financial vulnerability.

The balance sheet holds more cash than interest-bearing debt; net debt is -$45 million, indicating minimal leverage.

Cash accounts for 98.5% of assets versus 25.4% initially. The change indicates the degree of financial flexibility.

The balance sheet includes a negative accumulated result of -$611.1 million. It should be assessed alongside historical profits and capital distributions.

Balance sheet takeaway

Humanigen's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.

Annual Balance Sheet Humanigen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Net Debt

- -45 M -67.7 M 6.34 M 403 K 614 K -1.73 M -8.43 M 5 K -47.4 M -1.12 M -3.34 M - -

Long Term Debt

- 25 M - 6.49 M 1.22 M 1.35 M 1.27 M - - 6.79 M 9.83 M - - -

Total Non Current Liabilities

- - 2.34 M 1.25 M 1.22 M 1.35 M 1.27 M 5.41 M 311 K 6.79 M 10.2 M 400 K - -

Total Current Liabilities

56.2 M 68.7 M 20.4 M 13.6 M 8.26 M 24.7 M 7.82 M - 18.1 M 11.4 M 7.22 M 8.11 M - -

Total Liabilities

58 M 94.7 M 22.8 M 14.8 M 9.48 M 26 M 9.1 M 5.41 M 18.4 M 18.2 M 17.5 M 8.51 M - -

Deferred Revenue

883 K 4.14 M 1.87 M - - - - - - - - 5.63 M - -

Retained Earnings

-682 M -611 M -374 M -285 M -275 M -263 M -241 M -214 M -178 M -140 M -98.3 M -74.8 M - -

Total Assets

11.2 M 71.1 M 68.3 M 523 K 1.37 M 1.67 M 4.72 M 11.1 M 43 M 78.7 M 24.5 M 19.3 M - -

Cash and Cash Equivalents

10.2 M 70 M 67.7 M 143 K 814 K 737 K 3.01 M 8.43 M 10.9 M 54.2 M 10.9 M 3.34 M 8.9 M 4.75 M

Book Value

-46.8 M -23.7 M 45.5 M -14.3 M -8.11 M -24.3 M -4.38 M 5.73 M 24.6 M 60.5 M 7.08 M 10.8 M - -

Total Shareholders Equity

-46.8 M -23.7 M 45.5 M -14.3 M -8.11 M -24.3 M -4.38 M 5.73 M 24.6 M 60.5 M -94.9 M -72.3 M -70.4 M -65.8 M

All numbers in USD currency

Quarterly Balance Sheet Humanigen

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 25 M 22.5 M 25.2 M 25 M 24.8 M 24.6 M 24.4 M - - - 7.32 M 6.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - 2.34 M - - - 1.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

54.8 M 58 M 78.4 M 99.5 M 96.4 M 94.7 M 95.6 M 78 M 81.8 M 22.8 M 14.9 M 11 M 16.7 M 14.8 M 13.3 M 12.3 M 10.3 M 9.48 M 9.31 M 8.07 M 7.92 M 26 M 24.1 M 16.6 M 14.9 M 9.1 M 5.12 M 9.46 M 8.18 M 5.41 M 12.6 M 14.3 M 15.8 M 18.4 M 17.3 M 19.9 M 15.9 M 18.2 M 19.6 M 17.1 M 18.9 M 17.5 M 9.73 M 3.1 M 17.5 M 8.51 M 8.51 M 8.51 M -

Deferred Revenue

883 K 883 K 884 K 3.09 M 4.13 M 4.14 M 4.14 M 4.14 M 4.14 M 1.87 M 1.87 M 1.87 M 1.87 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5.63 M 5.63 M - 5.63 M 5.63 M 5.63 M -

Retained Earnings

-686 M -682 M -686 M -663 M -632 M -611 M -578 M -511 M -440 M -374 M -342 M -311 M -287 M -285 M -283 M -280 M -277 M -275 M -273 M -270 M -268 M -263 M -259 M -252 M -246 M -241 M -236 M -231 M -219 M -214 M -200 M -194 M -188 M -178 M -168 M -160 M -151 M -140 M -130 M -119 M -107 M -98.3 M -86.6 M -78 M -98.3 M -74.8 M -74.8 M -74.8 M -

Total Assets

5.12 M 11.2 M 26 M 49.4 M 71.3 M 71.1 M 77.9 M 122 M 98.8 M 68.3 M 92.1 M 42.6 M 432 K 523 K 594 K 1.59 M 730 K 1.37 M 2.61 M 1 M 2.51 M 1.67 M 2.57 M 1.92 M 6.03 M 4.72 M 4.93 M 13.5 M 8.49 M 11.1 M 16.7 M 24.7 M 32 M 43 M 51.1 M 61.3 M 66.6 M 78.7 M 57.9 M 66.2 M 79.2 M 24.5 M 28.3 M 29.7 M 24.5 M 19.3 M 19.3 M 19.3 M -

Cash and Cash Equivalents

3.1 M 10.2 M 24.7 M 47 M 68.9 M 70 M 76.5 M 121 M 92.9 M 67.7 M 91.4 M 41.7 M 68 K 143 K 157 K 1.09 M 180 K 814 K 2.04 M 267 K 1.56 M 737 K 1.1 M 103 K 4.04 M 3.01 M 2.9 M 11.9 M 6.58 M 8.43 M 7.65 M 16.1 M 12.6 M 10.9 M 11.3 M 9.05 M 33.4 M 54.2 M 23.3 M 19.5 M 69.9 M 10.9 M 6.42 M 9.92 M 10.9 M 3.34 M 3.34 M 3.34 M -

Book Value

-49.7 M -46.8 M -52.4 M -50.1 M -25 M -23.7 M -17.6 M 43.7 M 17 M 45.5 M 77.3 M 31.6 M -16.3 M -14.3 M -12.7 M -10.8 M -9.55 M -8.11 M -6.69 M -7.07 M -5.41 M -24.3 M -21.6 M -14.7 M -8.87 M -4.38 M -185 K 4 M 308 K 5.73 M 4.14 M 10.5 M 16.1 M 24.6 M 33.8 M 41.4 M 50.7 M 60.5 M 38.3 M 49.1 M 60.3 M 7.08 M 18.5 M 26.6 M 7.08 M 10.8 M 10.8 M 10.8 M -

Total Shareholders Equity

-49.7 M -46.8 M -52.4 M -50.1 M -25 M -23.7 M -17.6 M 43.7 M 17 M 45.5 M 77.3 M 31.6 M -16.3 M -14.3 M -12.7 M -10.8 M -9.55 M -8.11 M -6.69 M -7.07 M -5.41 M -24.3 M -21.6 M -14.7 M -8.87 M -4.38 M -185 K 4 M 308 K 5.73 M 4.14 M 10.5 M 16.1 M 24.6 M 33.8 M 41.4 M 50.7 M 60.5 M 38.3 M 49.1 M 60.3 M -94.9 M -83.5 M -75.4 M -94.9 M -72.3 M -72.3 M -72.3 M -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Humanigen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.31 6.5 % $ 166 M schweizSchweiz
ADMA Biologics ADMA Biologics
ADMA
$ 9.7 3.21 % $ 2.31 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.89 0.3 % $ 4.23 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 13.3 1.06 % $ 364 M israelIsrael
AbbVie AbbVie
ABBV
$ 265.08 0.02 % $ 469 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 193.45 0.24 % $ 9.62 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.28 2.24 % $ 28.1 M usaUSA
Adagene Adagene
ADAG
$ 2.97 0.62 % $ 175 M chinaChina
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.53 2.65 % $ 293 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.04 0.24 % $ 2.7 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 62.21 0.06 % $ 11.9 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.16 0.45 % $ 3.56 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.83 0.87 % $ 341 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.19 1.17 % $ 1.27 B usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.08 0.3 % $ 255 M usaUSA
Codexis Codexis
CDXS
$ 1.38 0.72 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 4.3 % $ 496 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.26 1.48 % $ 148 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.12 0.28 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.04 4.94 % $ 49.3 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.31 0.12 % $ 3.68 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 2.69 % $ 645 M usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.19 1.26 % $ 13.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.45 1.05 % $ 711 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 112.94 3.29 % $ 11.7 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.74 0.19 % $ 103 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.31 0.74 % $ 87.6 M usaUSA
Curis Curis
CRIS
$ 0.95 0.98 % $ 12.5 M usaUSA
CorMedix CorMedix
CRMD
$ 7.69 0.06 % $ 554 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.76 1.2 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 12.54 8.21 % $ 990 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.71 2.62 % $ 3 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.68 0.59 % $ 13.5 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 65.81 0.04 % $ 7.9 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 450.61 1.61 % $ 35.2 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.56 7.16 % $ 355 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.46 5.52 % $ 3.53 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.36 10.62 % $ 81.6 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.41 3.72 % $ 14.8 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.69 0.17 % $ 239 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 3.97 1.46 % $ 22.5 M usaUSA